The research paper, titled “Potential of Flavonoid-Inspired Phytomedicines against COVID-19,” indicates that the group’s research using the Equivir, Linebacker, and Caflanone compounds, may inhibit against Covid-19 receptors “equally or better” than Chloroquine, a drug currently under evaluation in clinical trials against COVID-19.
SINGAPORE (June 17): Singapore eDevelopment’s (SeD) wholly-owned subsidiary Impact Biomedical says that its Covid-19 research with Global Research and Discovery Group Sciences (GRDG) was published in the peer-reviewed scientific journal Molecules on June 11.
The research was conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. (Vilotos).
